Literature DB >> 23430446

Is the BCR-ABL1 transcript type in chronic myeloid leukaemia relevant?

Stephen E Langabeer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23430446     DOI： 10.1007/s12032-013-0508-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  3 in total

1.  Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Andrea Davies; Katy Knight; Sarah J Watmough; Lihui Wang; Richard E Clark
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

2.  A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts.

Authors:  Thomas Burmeister; Richard Reinhardt
Journal:  Leuk Res       Date:  2007-10-24       Impact factor: 3.156

3.  Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia.

Authors:  Ayda Bennour; Ines Ouahchi; Bechir Achour; Monia Zaier; Yosra Ben Youssef; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  Med Oncol       Date:  2012-12-27       Impact factor: 3.064
  3 in total
  8 in total

1.  Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts.

Authors:  Preetesh Jain; Carlos Guillermo Romo; Hanna J Khoury; Hagop Kantarjian; Jorge Cortes
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

2.  A Prognostic and Predictive Study of BCR-ABL Expression Based on Characterization of Fusion Transcripts.

Authors:  Vinal Upadhyay; Apexa Raval; Kanisha Shah; Franky D Shah; Rakesh Rawal
Journal:  Indian J Clin Biochem       Date:  2018-07-28

3.  Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.

Authors:  Preetesh Jain; Hagop Kantarjian; Keyur P Patel; Graciela Nogueras Gonzalez; Rajyalakshmi Luthra; Rashmi Kanagal Shamanna; Koji Sasaki; Elias Jabbour; Carlos Guillermo Romo; Tapan M Kadia; Naveen Pemmaraju; Naval Daver; Gautam Borthakur; Zeev Estrov; Farhad Ravandi; Susan O'Brien; Jorge Cortes
Journal:  Blood       Date:  2016-01-04       Impact factor: 22.113

4.  Chronic Myeloid Leukemia with an e6a2 BCR-ABL1 Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring.

Authors:  Mireille Crampe; Karl Haslam; Emma Groarke; Eileen Kelleher; Derville O'Shea; Eibhlin Conneally; Stephen E Langabeer
Journal:  Case Rep Hematol       Date:  2017-10-16

5.  Atypical presentation of patients with chronic myeloid leukemia in chronic phase-Case report.

Authors:  Florian Ramdohr; Alice Fabarius; Bettina Maier; Daniela Bretschneider; Anna Jauch; Astrid Monecke; Klaus H Metzeler; Johannes W G Janssen; Richard F Schlenk; Sabine Kayser
Journal:  Front Oncol       Date:  2022-08-29       Impact factor: 5.738

6.  Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report.

Authors:  Livia Manzella; Elena Tirrò; Silvia Rita Vitale; Adriana Puma; Maria Letizia Consoli; Loredana Tambè; Maria Stella Pennisi; Sandra DI Gregorio; Chiara Romano; Cristina Tomarchio; Francesco DI Raimondo; Fabio Stagno
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

7.  Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib.zzm321990A First of Its Kind Study on CML Patients of Kashmir

Authors:  Niyaz A Azad; Zafar A Shah; Arshad A Pandith; Mosin S Khan; Roohi Rasool; Javed Rasool; Shiekh A Aziz
Journal:  Asian Pac J Cancer Prev       Date:  2018-06-25

8.  Polymorphisms in the CYP2A6 and ABCC4 genes are associated with a protective effect on chronic myeloid leukemia in the Brazilian Amazon population.

Authors:  Natasha Monte; Karla B C C Pantoja; Juliana C G Rodrigues; Darlen C de Carvalho; Tereza C B Azevedo; Esdras E B Pereira; Paulo P de Assumpção; Sidney E B Dos Santos; Marianne R Fernandes; Ney P C Dos Santos
Journal:  Mol Genet Genomic Med       Date:  2021-05-29       Impact factor: 2.183
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.